Insmed announced that its latest study failed to meet both the predefined primary and secondary efficacy endpoints.

Based on this result, the company has decided to terminate further development of the HS project. The publication of the clinical trial results marks a pause in Insmed's exploration within the relevant therapeutic area. The company stated that it will continue to evaluate the progress of its other R&D pipelines and optimize resource allocation. The disclosure of this research data provides important reference points for investors and industry observers regarding the company's development progress. The market will closely monitor Insmed's subsequent strategic adjustments and pipeline layout.